This problem can be overridden by combined inhibition of S100A9-CXCL12 signaling with a PD-1 antibody (aPD-1), providing selective strategy for effective immunotherapy in breast cancers with elevated S100A9 and/or CXCL12 protein levels. This evidence concerns the gene S100A9 and breast carcinoma.